Furthermore, encouraging clinical outcomes have also been reported with tebentafusp, the first approved TCR therapeutic, which targets the gp100 peptide and redirects T cells via CD3 engagement for the treatment of uveal and malignant melanoma.66 This evidence concerns the gene PMEL and melanoma.